Latest Commercialisation News

Immuron Limited posted a 6% rise in FY26 sales to $7.7 million, improved its net loss by $1.4 million, and secured FDA approval for IMM-529, underpinning a strategic pivot towards profitability and geographic expansion.

Bisalloy Steel’s FY26 profit fell 16% as softer domestic demand and Indonesian import restrictions weighed, but the company secured a pioneering US submarine steel order and advanced its digital wear-monitoring technology.

Weebit Nano surged to record revenue of $15.3 million in FY26, fueled by key licensing deals and product tape-outs, while investing heavily in R&D and AI initiatives. Despite a $54.9 million loss, a $102 million capital raise leaves the company well-positioned for growth.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Syntara Limited’s FY2026 results show a 7.9% revenue decline and a 13.6% increase in net loss amid significant clinical progress, including FDA backing for its lead drug amsulostat and a successful $8.8 million capital raise.

Biotron Limited posted a $1.52 million net loss for FY2026, driven by integration and R&D costs following its Sedarex acquisition, while progressing regulatory and clinical development for its SedRxTM anaesthetic and antiviral pipeline.

Clarity Pharmaceuticals reported a 67% increase in net loss to $107.2 million for FY26, driven by higher R&D spending, while advancing multiple Phase III trials and expanding manufacturing capacity ahead of commercialisation.

Integrated Research’s FY26 results reveal a sharp 91% drop in net profit amid softer renewals and rising expenses, offset by a 27% jump in cash and a special dividend. The company pushes forward with AI-powered products despite early-stage commercialisation risks.

Argent BioPharma has secured a key FDA regulatory milestone with the establishment of an Investigational New Animal Drug (INAD) file for its CannEpil veterinary program, targeting cancer-related pain in companion animals.

Strata Investment Holdings delivered a £16.48 million comprehensive profit for H1 2026, driven by a strong revaluation of its investment portfolio and maiden royalty income from Botswana copper assets.

Nickel Industries surged to a US$74 million profit in H1 2026, driven by higher nickel prices, expanded mining quotas, and strategic HPAL investments including first nickel cathode production at ENC.

Sierra Nevada Gold (ASX: SNX) has completed a $12.85 million capital raise to fund an aggressive Phase 2 drilling campaign at its As Safra Copper-Gold Project in Saudi Arabia, supported by strong institutional backing.